Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry

BACKGROUND: Based on the excellent results of the clinical trials with ALK-inhibitors, the importance of accurately identifying ALK positive lung cancer has never been greater. However, there are increasing number of recent publications addressing discordances between FISH and IHC. The controversy i...

Descripción completa

Detalles Bibliográficos
Autores principales: Conde, Esther, Suárez-Gauthier, Ana, Benito, Amparo, Garrido, Pilar, García-Campelo, Rosario, Biscuola, Michele, Paz-Ares, Luis, Hardisson, David, de Castro, Javier, Camacho, M. Carmen, Rodriguez-Abreu, Delvys, Abdulkader, Ihab, Ramirez, Josep, Reguart, Noemí, Salido, Marta, Pijuán, Lara, Arriola, Edurne, Sanz, Julián, Folgueras, Victoria, Villanueva, Noemí, Gómez-Román, Javier, Hidalgo, Manuel, López-Ríos, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172507/
https://www.ncbi.nlm.nih.gov/pubmed/25248157
http://dx.doi.org/10.1371/journal.pone.0107200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172507/
https://www.ncbi.nlm.nih.gov/pubmed/25248157
http://dx.doi.org/10.1371/journal.pone.0107200

Ejemplares similares